Edgewise Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Key cardiovascular and neuromuscular programs are advancing, with 7500 showing a favorable safety profile and plans for Phase III in HCM by year-end. Becker muscular dystrophy data indicate disease stabilization, and new HFpEF candidates are progressing.
-
Major milestones include an upcoming phase III readout for sevasemten in Becker, CIRRUS Part D data in HCM, and phase I initiation for EDG-15400. Enhanced trial designs and strong patient retention support commercial prospects, with phase III HCM trials set for Q4.
-
Major clinical programs in Becker muscular dystrophy and hypertrophic cardiomyopathy are advancing, with pivotal data readouts and regulatory submissions expected in the next 12–18 months. Strong efficacy, safety, and financial position support commercial launch readiness and expansion into multi-billion dollar markets.
Fiscal Year 2025
-
Significant progress was made in both Becker muscular dystrophy and HCM programs, with key biomarker and efficacy endpoints met and improved safety protocols implemented. Phase 3 trials are on track, and eliminating echo monitoring could expand market access.
-
Upcoming December data will highlight the 25 mg dose's efficacy and safety in new HCM patient cohorts, with a focus on ejection fraction stability and broader market potential. The 12-week study and pivotal Grand Canyon readout remain on track, while commercial and pipeline preparations advance.
-
Strong efficacy and safety data support the drug's differentiation from current therapies, with protocol changes improving patient selection and trial design. Plans include pivotal trials in HCM and HFpEF, regulatory engagement for DMD, and a well-funded path to commercialization.
-
Sevasemten showed sustained disease stabilization and favorable safety in Becker and Duchenne muscular dystrophy, with pivotal Grand CANYON phase III fully enrolled and top-line data expected in late 2026. FDA feedback supports the approval path, and the company is well-funded for upcoming milestones.
-
Multiple late-stage programs are advancing in muscular dystrophy and HCM, with key data readouts and regulatory milestones expected in the coming year. The HCM drug's unique safety and efficacy profile positions it for broad adoption, especially in non-obstructive patients.
-
EDG-7500 demonstrated strong symptomatic improvement in HCM without reducing ejection fraction, with dose optimization strategies being developed to maximize patient benefit. Upcoming 12-week data may show further efficacy, and DMD program updates are expected mid-year.
-
EDG-7500 demonstrated robust efficacy in both obstructive and non-obstructive HCM, with significant reductions in LVOT gradient and NT-proBNP, and marked improvements in quality of life and functional status, all without reducing ejection fraction. The safety profile was favorable, and future studies will focus on dose optimization and broader patient access.
-
Upcoming 28-day data for EDG-7500 in HCM will assess efficacy and safety, while sevasemten's strong biomarker and functional results in Becker muscular dystrophy support an accelerated approval path. Over-enrollment in trials and a differentiated safety profile position both assets for broad market impact.
-
Significant progress was made in advancing therapies for muscular dystrophies and hypertrophic cardiomyopathy, with pivotal studies fully enrolled and promising clinical data supporting regulatory engagement. Strong financials and a robust pipeline position the company for multiple milestones in 2024–2026.
Fiscal Year 2024
-
Sevasemten showed significant reductions in muscle damage biomarkers and stable function in Becker patients during the Canyon phase 2 trial. The Grand Canyon phase 3 study is nearly fully enrolled, with regulatory discussions and global expansion planned.
-
The phase II CANYON trial of Sevesantan in Becker muscular dystrophy met its primary endpoint, showing significant reductions in muscle damage biomarkers and functional stabilization versus placebo, with a favorable safety profile. These results support ongoing pivotal trials and regulatory engagement.
-
CANYON trial data is imminent, aiming for clinically meaningful efficacy and robust biomarker changes, with pivotal GRAND CANYON fully enrolled. HCM MAD study is advancing, targeting both obstructive and non-obstructive populations, and strategic interest is high as pivotal studies are planned for 2026.
-
EDG-7500, a novel cardiac sarcomere modulator, showed strong safety and efficacy in phase 1 and phase 2 studies, reducing cardiac gradients and NT-proBNP without lowering ejection fraction in HCM patients. Ongoing studies will assess longer-term dosing and broader patient outcomes.